Follow the Artiva Biotherapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €559.8m. The latest transaction was disclosed on 18 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: RA CAPITAL MANAGEMENT, L.P.. Every trade is free.
63
Insider Decl.
n/a
Thresholds
€18m
21 ops.
Buy Volume
€147,065
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Artiva Biotherapeutics, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$35.80.
42Σ signal
Buys €18m€147,065 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Artiva Biotherapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias celulares para el tratamiento del cáncer. Utiliza tecnologías innovadoras para mejorar los resultados de los pacientes.